Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
CME Journal Supplement Provided by CME Institute
Volume 84 | 2023 | Supplement 1
Supported by an unrestricted educational grant from Sage Therapeutics, Inc.
Now that you’ve read the print supplement, continue here to watch Kristina M. Deligiannidis, MD and Anita H. Clayton, MD discuss MDD and PPD. At the end of this page, click to complete the posttest to earn free AMA PRA Category 1™ credit.
Inadequacies of Suboptimal Depression Treatment
Kristina M. Deligiannidis, MD and Anita H. Clayton, MD highlight gaps in treating major depression and postpartum depression, particularly relating to adherence, adverse events, efficacy, polypharmacy, first-line switching, and treatment resistance.
Underlying Neurobiology of MDD and PPD
Neuroactive steroids play an important role in the neurobiology of depression as an allosteric modulator of GABAergic and glutamatergic transmission signaling, affecting HPA axis functioning and offering a new therapeutic target approach in the treatment of the disorder.
Clinical Trial Data for Approved and Emerging GABA-targeting Neuroactive Steroids
With clinical recognition of the importance of neurosteroids in the modulation of GABAA signaling pathways, researchers have developed novel neuroactive steroid-based pharmacotherapies which have been tested in clinical studies and have the potential to change the treatment paradigm for MDD and PPD.